Contents
29 April 2020
Vol 12, Issue 541
Vol 12, Issue 541
Research Articles
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
A ribonucleoside analog inhibits SARS-CoV-2 in human airway epithelial cell cultures and SARS-CoV and MERS-CoV in mice.
- Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors
AZD3229 demonstrates pan-KIT/PDGFRα activity in several preclinical models and is a promising agent for the treatment of GIST.
- CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model
CDK12 inhibition reduces mutant transcripts and nuclear foci in DM1 cells and produces splicing correction and phenotypic benefit in a mouse model.
- Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition
Vascular oxidative stress in human atherosclerosis is reversed by restoring vascular insulin sensitivity using a dipeptidyl peptidase 4 inhibitor.
- Lactation improves pancreatic β cell mass and function through serotonin production
Lactation benefits women’s metabolic health by improving pancreatic β cell mass and function through serotonin production in β cells.
Editors' Choice
- An ounce of public health for COVID-19?
Multifaceted nonpharmaceutical interventions supported by data restricted spread of COVID-19 in China.
- An ACE therapy for COVID-19
Recombinant human soluble ACE2 inhibits SARS-CoV-2 viral infection in human organoids in vitro.
- Glucose and the brain: A new target in diabetes
Central insulin-independent modulation of KATP channels by hyperglycemia decreases glucose production by the liver.
About The Cover
ONLINE COVER Emerging Antivirals. Bats can harbor viruses such as severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) that are primed for zoonotic transmission to humans. As SARS-CoV-2 wreaks havoc across the globe, scientists are scrambling to develop new diagnostics and therapeutics to detect and treat this dangerous pathogen. Sheahan et al. now test the ability of a broad-spectrum antiviral drug to inhibit multiple bat-derived coronaviruses in cells and mice. Testing in primary human airway epithelial cell cultures showed efficacy of this drug against SARS-CoV-2 as well as blunted disease in mice infected with related coronaviruses. The drug, a ribonucleoside analog that disrupts viral RNA replication, can be administered orally as a pill and potentially could provide broad coverage to combat coronaviruses and other RNA viruses. [CREDIT: CHIEN LEE/MINDEN PICTURES]
